ΕΚΕ 2012 1 Hellenic PCI Registry (2008-2011) Περιεχόμενο και αναγκαιότητα διατήρησης Registry Αγγειοπλαστικής Georgios.

Slides:



Advertisements
Similar presentations
Introduction Recent guidelines considered PCI to be a potential alternative to CABG for ULMCA stenosis, based on several large registries and randomized.
Advertisements

Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
A Risk Score for Predicting Coronary Artery Bypass Surgery in Patients with Non-ST Elevation Acute Coronary Syndromes Sai Sadanandan, MD*; Christopher.
CPORT- E Trial Randomized trial comparing medical, economic and quality of life outcomes of non-primary PCI at hospitals with and without on-site cardiac.
Complications of HSRA Layth A. Mimish Consultant Cardiologist Cardiovascular Consultants Group Jeddah, Saudi Arabia.
BWGIC survey Victor Legrand Yves Taeymans. PCI 2004 : procedures n=
STEMI Due to Stent Thrombosis: An Enlarging Subgroup of High Risk Patients Bruce Brodie, Adam Bensimhon, Nathan Fleishman, Charles Hansen, Mike Cooper,
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
Francesco Liistro Cardiovascular Department, Arezzo, Italy Impact of Thrombus Aspiration on Myocardial Tissue Reperfusion and Left Ventricular Functional.
WG Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,
Chaim Lotan MD, Yaron Almagor MD, Karel Kuiper MD, M.J. Suttorp MD, William Wijns MD The SICTO Study CYPHER TM Sirolimus-eluting stent in Chronic Total.
Around-the-Clock Primary Angioplasty: A Process of Care Analysis Comparing Off-Hours and Normal Hours Treatment of Acute STEMI R Leung, D Lundberg, D Galbraith,
ACS and Thrombosis in the Emergency Setting
SCAAR UCR SWEDEN 2007 Stefan James, Jörg Carlsson, Johan Lindbäck, Tage Nilsson, Ulf Stenestrand, Lars Wallentin and Bo Lagerqvist for the SCAAR study.
Proxis Proximal embolic protection in saphenous vein graft and infarct PCI Dan Blackman Leeds General Infirmary Advanced Angioplasty 2006.
ICE Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Efficacy of high dose atorvaSTATIN loading before primary percutaneous coronary intervention in ST Elevation Myocardial Infarction (STATIN STEMI) Jung-Sun.
Female Gender Is An Independent Predictor Of In-Hospital Mortality After STEMI In The Era of Primary PCI. Insights From The Greater Paris Area PCI Registry.
ARMYDA-5 (Antiplatelet therapy for Reduction of MYocardial Damage during Angioplasty) Study Prospective, multicenter, randomized trial investigating influence.
Tarunjit Singh Department of Internal Medicine Westchester Medical Center New York Medical College Valhalla NY.
Athens Cardiology Update CADILLAC Study Blood Transfusion after Myocardial Infarction: Friend, Foe or double-edged Sword? Georgios I. Papaioannou,
Bleeding in Patients Undergoing Percutaneous Coronary Interventions: A Risk Model From 302,152 Patients in the NCDR. Sameer K. Mehta MD, Andrew D. Frutkin.
Left Main Trifurcation Disease: Early and Long-Term Outcomes Of Percutaneous Coronary Intervention I.Sheiban, A.Gerasimou, F. Sciuto, P.Omedè, G. Biondi.
RESEARCH, REDUCE III, X-AMINE ST, COOL-MI Azfar Zaman Freeman Hospital, Newcastle.
ICE Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD,
Endeavor Safety: Pooled Analysis of Early and Late Safety of a Zotarolimus-Eluting Stent Laura Mauri, MD, MSc Brigham and Women’s Hospital Harvard Clinical.
Samsung Medical Center Cardiac & Vascular Center Young Bin Song, Joo-Yong Hahn, Seung-Hyuk Choi, Jin-Ho Choi, Sang Hoon Lee, Myung-Ho Jeong, Hyo-Soo Kim,
Basel Stent Cost-Effectiveness (BASKET) Trial BASKET Trial Presented at The European Society of Cardiology Hotline Session 2005 Presented by Dr. Matthias.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Name of the speaker: Germano DiSciascio I have the following potential conflicts of interest to report:  Consulting  Employment in industry  Stockholder.
Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)
ADMIRALADMIRAL Abciximab before Direct Angioplasty and Stenting in Myocardial Infarction Regarding Acute and Long term follow-up ADMIRAL Study ADMIRAL.
Clinical Experience with the Bio Active Stent (BAS) in FINLAND 9 e CFCI Hotel Meridien Etoile Paris, France 10 Octobre 2007 Pasi Karjalainen, MD, PhD.
Balloon-pump assisted Coronary Intervention Study BCIS-1 Simon Redwood Divaka Perera, Rod Stables, Martyn Thomas.
Allen Jeremias, Neal Kleiman, Deborah Nassif, Wen-Hua Hsieh, Michael Pencina, Kelly Maresh, Manish Parikh, Donald Cutlip, Ron Waksman, Steven Goldberg,
Multivessel Coronary Artery Disease
Issued in 2014 – SCAAR. SCAAR Annual report 2013.
Issued in 2015 – SCAAR. SCAAR Annual report 2014.
Columbia University Medical Center Cardiovascular Research Foundation New York City, NY Akiko Maehara, MD Use of IVUS Reduces Stent Thrombosis and Myocardial.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
Hybrid Off-Pump Revascularization; Early & Midterm Results 서울대학교병원 흉부외과 황 호영, 조 광리, 김 기봉.
No conflicts of interest or financial ties to disclose.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
M-Guard stent in STEMI patients with high thrombus burden lesions Mahmoud Shabestari Baktash Bayani Ali Eshraghi Bahram Shahri Mashhad University.
The OPTIMAX first-in-man study Mid-term clinical outcome of Titanium-Nitride-Oxide-coated Cobalt Chromium stents in patients with de novo coronary artery.
A Clinical profile of patients enrolled in the Pakistan ACS registry
Latvian Centre of Cardiology real-life registry
Interesting Case Presentation
CRT 2017 Interventional Challenging Case Anterior ST- Elevation Myocardial Infarction Resulting From Acute Occlusion of Left Internal Mammary Artery Graft.
Procedural factors associated with PCI-related ischemic stroke
BVS Expand: First Results of Wide Clinical Applications
Stent Thrombosis Rates in Contemporary Clinical Practice: Insight from a Large Australian Multi-centre Registry BP Yan*, TJ Kiernan, SJ Duffy, DJ Clark,
Is There a Role for Aspiration in STEMI?
On behalf of J. Belardi, M. Leon, L. Mauri,
FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL
Incidence And Management Of Restenosis After Treatment Of Unprotected Left Main Disease With Drug-Eluting Stents: 70 Restenotic Cases From A Cohort Of.
Giuseppe Biondi Zoccai, MD
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
Impact of clopidogrel loading dose on the safety and effectiveness of bivalirudin in patients undergoing primary angioplasty for acute myocardial infarction:
Large-Scale Registry Examining Safety and Effectiveness of Zotarolimus-Eluting and Sirolimus-Eluting Stents in Patients with Coronary Artery Disease Western.
Hellenic PCI Registry Organization - Structure - Directions - Initial Recordings Georgios I. Papaioannou, MD, MPH, FACC,
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Angioplasty Balloon-associated Coronary Debris and the EZ FilterWire
Ahmed A. Khattab, MD For the German Cypher Registry Investigators
Atlantic Cardiovascular Patient Outcomes Research Team
The American College of Cardiology Presented by Dr. A. Abazid
Presentation transcript:

ΕΚΕ Hellenic PCI Registry ( ) Περιεχόμενο και αναγκαιότητα διατήρησης Registry Αγγειοπλαστικής Georgios I. Papaioannou, MD, MPH, FACC, FSCAI Athens Medical Center Cardiac Catheterization Laboratory 18/2/2012

ΕΚΕ Aim of the Hellenic PCI Registry ( ) Common link with ESC (ESC PCI Registry) and EAPCI Recording of Centers/Operators/ Interventional Coronary Procedures with regional and national analyses Recording of basic indications, demographic, procedural and outcomes data of patients undergoing PCI National database for educational and professional requirements (in accordance to ESC/ACC) Quality and Outcomes Research

ΕΚΕ Registries & Clinical Practice

ΕΚΕ Timetable of the PCI Registry 5/2006:WG decision 7/2006:Funding for the initial phase 9/2006:Collaboration with Philip Lees (Webmaster) 12/2006:Early design of database 3/2007:Testing version in a separate domain (Phase I) 7/2007:Phase II – Pilot cases entry (>300 patients, 9 centers) 2/2008:Phase III – Official start of Registry retrospectively from 1/1/2008 with a 3-5 year plan (>2500 patients entered so far) 2/2011:3 year completion – Analyses of more than 4000 entries (National/Hospital/User level)

ΕΚΕ Tables (8) Patient (Automatic entry ID-Demographics-Patient initials) Workup (History-Risk factors-Indication-Times-Admission Medications) PCI Angiogram (Angiographic findings based on the 15- segment model of ESC) PCI Procedure (Periprocedural medications-Additional diagnostic or theurapeutic devices-Complications) PCI Lesions (Lesion characteristics-PCI device-Result) Outcome (In-hospital outcome) Follow up (1 year/3 years/5 years) Submit (Automatic initial validation)

ΕΚΕ PCI Centers: 2011

ΕΚΕ COR Procedures

ΕΚΕ PCI Procedures

ΕΚΕ PCI Volume per Center:

ΕΚΕ Primary PCI numbers: * 2011: Estimated numbers

ΕΚΕ Hellenic PCI Registry (2/ /2010) n=3441 validated patients: Demographics Males2859 (83.1%) Females582 (16.9%) Age64.1 ± 11.1 Height169.8 ± 10.8 Weight81.9 ± 14.9 BMI27.9 ± 3.9

ΕΚΕ Hellenic PCI Registry (2/ /2010) n=3441 patients: Demographics Hx Stable Angina 877 (25.5%) Hx Prior MI 797 (23.2%) Hx CVA 56 (1.6%) Hx PVD 171 (4,9%) Hx of CRF 83 (2.4%) Hx Prior PCI 726 (21.1%) Hx Prior CABG 225 (9.1%) Current Smokers 1337 (38.9%) Former Smokers 1079 (31.4%) Current Diabetes 1029 (29.9%) Oral Agents - IDDM (17.5% - 4.9%) Hypertension 2392 (69.5%) Dyslipidemia 2311 (67.1%)

ΕΚΕ Hellenic PCI Registry (2/ /2010) n=3441 patients: PCI Indication Elective PCI*1622 (47.1%) ACS (UA/NSTEMI) 441 (12.8%) STEMI284 (8.3%) ACS stabilized622 (18.1%) STEMI stabilized 458 (13.3%) Other14 (0.4%) *Stable angina/documented ischemia

ΕΚΕ Hellenic PCI Registry (2/ /2010) n=742 STEMI patients: Type of Therapy Thrombolysis prior PCI267 (35.9%) Primary PCI225 (30.3%) Delayed PCI517 (69.7%)

ΕΚΕ Hellenic PCI Registry (2/ /2010) n=225 STEMI Primary PCI Patients: Times Mean symptom to door (min)249 Mean door to balloon (min)140 Door to balloon < 120 min147 (65.3%) Door to balloon < 90 min130 (57.7%)

ΕΚΕ Hellenic PCI Registry (2/ /2010) n=3441 patients: Angio Data EF >50% 2460 (71.5%) 30%  EF  50% 647 (18.7%) EF<30% 84 (2.5%) EF Unknown 250 (7.3%) LM>50% 93 (2.7%) 1VD 1754 (51%) 2VD 1087 (31.6%) 3VD 598 (17.4%) Cardiogenic Shock 18 (0.5%) Treated LM 67 (1.2%) Treated LAD* 2189 (39.6%) Treated CX* 1440 (26.1%) Treated RCA* 1825 (33.1%) Treated by-pass graft 116 (2.1%) *Lesions

ΕΚΕ Hellenic PCI Registry (2/ /2010) n=3441 patients: PCI Data Femoral Access3299 (95.9%) Radial Access109 (3.2%) IVUS74 (2.2%) Pressure wire67 (1.9%) IABP7 (0.2%) Distal Protection17 (0.5%) Thrombectomy150 (4.3%) Vascular closure device1135 (32.9%)

ΕΚΕ Hellenic PCI Registry (2/ /2010) n=3441 patients – 5521 Lesions: PCI Data Type A lesion 637 (11.5%) Type B lesion 3454 (62.6%) Type C lesion 1430 (25.9%) Restenosis - Bifuraction (3.6% %) Direct stenting 876 (15.9%) PCI with stent 5161 (93.5%) Mean number stent(s) per patient 1.74 Mean number stent(s) per lesion 1.14 Mean stent size (mm) 3.08 Mean stent length (mm) Multi-segment PCI 3517 (63.7%) Successful PCI 5378 (97.4%) BMS stenting* 1060 (19.2%) DES stenting* 4097 (74.2%) * Stent not specified: 362 (6.6%)

ΕΚΕ Hellenic PCI Registry (2/ /2010) n=3441 patients: Concurrent PCI Management Clopidogrel prior PCI 2051 (59.6%) mg 1765 (51.3%) mg 286 (8.3%) --- <6 hrs 626 (30.5%) --- >6 hrs 1425 (59.5%) Clopidogrel during PCI 1364 (39.6%) mg 857 (62.8%) mg 507 (37.2%) GIIbIIIa inhibitors (upstream) 99 (2.9%) GIIbIIIa inhibitors (procedural) 383 (11.1%)

ΕΚΕ Hellenic PCI Registry (2/ /2010) n=3441 patients: Complications & Outcomes Periprocedural complications 105 (3.1%) Acute segment closure 21 (0.6%) Side branch occlusion 28 (0.8%) Distal embolization 12 (0.3%) Coronary perforation 13 (0.4%) No flow/slow flow 31 (0.9%) In hospital death 18 (0.5%)* Periprocedural MI 35 (1.0%)* Periprocedural CVA 15 (0.4%) MACE (Death/MI/CVA) 65 (1.9%) Stent thrombosis 15 (0.4%) Repeat PCI 16 (0.5%) Emergency CABG 4 (0.1%) Major bleed 21 (0.6%) Renal failure 11(0.3%) * 1.2% ESC PCI Registry for Death and MI

ΕΚΕ Hellenic PCI Registry ( ) n=2191 validated patients: Outcomes* Death15 (0.7%) Myocardial Infarction22 (1.0%) CVA9 (0.4%) MACE44 (2.0%) *Improved reporting of outcomes (mainly death) as Registry evolves – Pending non-validated entries in 2010 with outcomes

ΕΚΕ Registry General Issues National vs Regional “Selective” National “Selective” Regional Individual Hospital –Type of information / patients (?ACS only) –Amount of information –Obligation of filling

ΕΚΕ Financial Issues

ΕΚΕ Registry Benefits Data on all patients having PCI Data on ACS – Stent-for-life initiative Type of care – Areas of improvement in ACS patients Number of operators – Hospitals with Cath Lab facilities – Regional differences Type of interventional procedures (expanding to non-coronary cases too)

ΕΚΕ Difficulties & Problems Motivation of physicians (multifactorial) Politics Clear understanding of the role and the benefits of the registry with broad participation in analyses Establish a structure especially in high-volume centers for secretarial help Loss of enthusiasm of existing users if a wide participation can not be achieved

ΕΚΕ Proposal to WG Continue keeping the existing structure of the Database (web site – server) with full- time professional(s) Complete a 3 year recording (2/2011) (done already) Establish software for National/Center/User analysis of entries (in plan) Decision regarding a “Selective” National Registry with aim to cover representative patients/data across the whole country

ΕΚΕ Participating Hospitals (>20 entries) *Top 3 Hospitals

ΕΚΕ Participating Physicians (Alphabetic order >10 entries) *Top 3 Physicians